Vir Biotechnology, Inc.
VIR
Key stats
- Open
- 12.90
- Day high
- 12.96
- Day low
- 12.02
- Previous close
- 13.13
- Volume
- 2.06M
- VWAP
- 11.98
- 52-week high
- 14.38
- 52-week low
- 5.32
- Market cap
- 2.25B
- Shares out
- 171.27M
- Employees
- 367
- Listed
- 2019
About Vir Biotechnology, Inc.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SAN FRANCISCO, CA · vir.bio
Options · expiring Nov 20
Nov 12, 4:00 PM ET- Call open interest
- 2.0K
- Put open interest
- 571
- Put/call
- 0.29
- At-the-money IV
- 241.8%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 10 call | 3.80 | Nov 9, 3:24 PM | 115 | 511 | 316.3% |
| 12 call | 0.75 | Nov 12, 3:54 PM | 15 | 512 | 177.9% |
| 13 call | 0.32 | Nov 12, 1:12 PM | 11 | 406 | 203.2% |
| 11 call | 1.55 | Nov 12, 2:47 PM | 10 | 560 | 241.8% |
| 12 put | 0.50 | Nov 12, 2:47 PM | 4 | 14 | — |
| 13 put | 0.55 | Nov 11, 3:54 PM | 3 | 3 | — |
Quarterly results
Massive · Nov 4, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | −$188.0K | $238.95M | −$29.0K | $64.07M |
| Gross profit | −$188.0K | $238.95M | −$29.0K | $64.04M |
| Operating income | −$104.66M | $73.47M | −$132.29M | −$47.92M |
| Net income | −$96.25M | $80.08M | −$125.69M | −$42.92M |
| Diluted EPS | -0.57 | 0.47 | -0.85 | -0.31 |
| Operating cash flow | −$106.08M | $123.33M | −$132.39M | −$25.88M |
| Assets | $1.11B | $1.21B | $1.03B | $1.00B |
| Liabilities | $215.82M | $232.31M | $212.82M | $237.55M |
| Equity | $896.04M | $982.49M | $812.76M | $765.28M |
Technicals
Massive · Nov 12, 2026- 50-day average11.18
- 200-day average9.75
- RSI (14 days)54.1
Short interest
Massive · Oct 30, 2026- Oct 30, 202616.87M shares · 11.9 days to cover
- Oct 15, 202616.24M shares · 6.9 days to cover
- Sep 30, 202614.98M shares · 7.0 days to cover
- Sep 15, 202619.66M shares · 9.5 days to cover
Dividends
Massive · Nov 3, 2010- Ex Nov 3, 2010, paid Dec 3, 20100.0250 · 4 a year
- Ex Aug 25, 2010, paid Sep 17, 20100.0250 · 4 a year
- Ex May 12, 2010, paid Jun 11, 20100.0250 · 4 a year
- Ex Mar 3, 2010, paid Mar 19, 20100.0250 · 4 a year
- Ex Nov 6, 2009, paid Dec 1, 20090.0250 · 4 a year
- Ex Aug 28, 2009, paid Sep 15, 20090.0250 · 4 a year
- Ex May 1, 2009, paid Jun 2, 20090.0250 · 4 a year
- Ex Feb 19, 2009, paid Mar 9, 20090.0250 · 4 a year
News coverage
No stories about Vir Biotechnology, Inc. right now.